Posted on June 14, 2017 | By Pharmacy OneSource
June 14, 2017 – Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, is showcasing its Sentri7® advanced surveillance and clinical decision support solution at the annual conference of the Association for Professionals in Infection Control and Epidemiology (APIC). The solution offers a comprehensive approach to identifying, tracking and reporting infection prevention issues, streamlining workflows and promoting outcomes improvement.
HAIs are a focal point of multiple national regulatory movements related to quality improvement as the U.S. aims to reduce mortality rates and costs—reaching as high as $45 billion—of these preventable conditions. According to the New England Journal of Medicine, 721,000 HAIs occur every year, and 75,000 are fatal.
“The increased regulatory focus on HAIs along with mandatory reporting to the National Health Safety Network (NHSN) has put healthcare providers’ reputations and financial performance at risk,” said David A. Del Toro, President & CEO of Clinical Software Solutions at Wolters Kluwer. “Sentri7 equips infection prevention professionals with the tools needed to streamline burdensome manual workflows and move clinical response from reactive to proactive.”
Sentri7 has a proven track record of decreasing the incidence of central line-association bloodstream infections, catheter-associated urinary tract infections and Clostridium difficile (C.diff) in hospitals across the U.S. The findings of a recent study attribute a 23% reduction in expected C.diff to use of real-time alerts that ensured early identification and proper management of at-risk patients. Encompassing 64 U.S. acute care hospitals affiliated with a central organization, the study measured performance against the Standardized Infection Ratio (SIR) for hospital-associated infections (HAI), a reporting requirement laid out by the Centers for Medicare and Medicaid Services in its Hospital-Acquired Condition Reduction Program for FY 2017.
Sentri7 automates surveillance of infections, standardizes and speeds outbreak investigations and expedites mandated reporting, including NHSN. The solution supports multiple infection prevention responsibilities, including investigation of HAIs, isolation management, multi-drug resistant organism (MDRO) management and compliance with federal and state reporting requirements.
In tandem with infection prevention, Sentri7 addresses antimicrobial stewardship initiatives—a critical strategy for managing MDROs and reducing the incidence of HAIs. Expanded functionality will soon address the need for accurate and efficient tracking of antimicrobial usage and one-click reporting to NHSN.
To learn more, visit us at Booth 450 during the 44th Annual Conference of APIC.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Written for clinicians